Scalper1 News
A panel of outside experts called by the FDA gave largely negative feedback on BioMarin Pharmaceuticals’ muscular-dystrophy drug candidate Tuesday in a hearing that investors, patients and makers of rival drugs watched closely. There’s been no consensus on Wall Street as to whether the FDA will approve drisapersen, a drug that failed to hit its primary endpoint in two phase-two studies and one phase-three study. But BioMarin (BMRN) argued that the Scalper1 News
Scalper1 News